Standard Operating Procedure for Coordination Between CMC and Regulatory Affairs Teams
| Department | Regulatory Affairs |
| SOP No. | RA/2026/710 |
| Supersedes | NA |
| Page No. | 1 of X |
| Issue Date | 13/04/2026 |
| Effective Date | 13/04/2026 |
| Review Date | 13/04/2028 |
Purpose
This Standard Operating Procedure (SOP) defines the structured process for effective coordination and communication between the Chemistry, Manufacturing, and Controls (CMC) team and the Regulatory Affairs team. The purpose is to ensure seamless exchange of accurate, timely, and compliant documentation and information relating to product development, regulatory submissions, dossier updates, and lifecycle management. This SOP supports the control objective of maintaining regulatory compliance, timely dossier submissions, and alignment of scientific and regulatory strategies to facilitate product approvals and ongoing regulatory interactions.
Scope
This SOP applies to all activities involving collaboration between the CMC and Regulatory Affairs departments related to pharmaceutical product development, dossier preparation and submission, regulatory queries, compliance documentation, and post-approval modifications. It covers coordination for all dosage forms, processes, equipment qualification status, validation data, analytical documentation, manufacturing controls, and associated documentation workflows. The SOP excludes activities solely within either department that do not require interdepartmental coordination.
Responsibilities
The following functional roles are involved in executing, reviewing, supervising, verifying, and documenting coordination activities under this SOP:
- CMC Scientists and Specialists: Prepare technical data, batch records, validation/qualification reports, and product specification documents intended for regulatory submission.
- Regulatory Affairs Officers and Managers: Review and consolidate CMC data, prepare regulatory dossiers, respond to agency queries, and submit documentation to health authorities.
- Quality Assurance Personnel: Oversee compliance of documentation and processes, and perform internal reviews as required.
- Document Control Staff: Manage document versioning, archival, and controlled distribution in accordance with organizational policies.
- Department Heads/Team Leads: Supervise activities, ensure adequate resource allocation, and confirm adherence to timelines and regulatory requirements.
Accountability
The Head of Regulatory Affairs is accountable for the overall implementation, compliance, and periodic review of this SOP. This role is responsible for escalation of deviations, coordination of corrective and preventive actions (CAPA), ensuring continuous improvement of coordination processes, and verifying effectiveness at scheduled intervals.
Procedure
This procedure details systematic steps for coordinated interaction between CMC and Regulatory Affairs teams to ensure compliant dossier management and regulatory submission excellence.
1. Preparation and Prerequisites: Ensure that all data, reports, and documentation generated by CMC teams are current, complete, and comply with regulatory standards. Confirm qualification or validation status of relevant equipment and processes prior to data submission. Regulatory Affairs should familiarize with applicable regional regulatory requirements to guide dossier preparation accurately.
2. Initial Communication: Regulatory Affairs initiates coordination by providing CMC teams with up-to-date regulatory submission timelines, dossier format requirements, and templates reflecting applicable guidelines. CMC teams acknowledge and plan deliverables accordingly.
3. Data Compilation and Review: CMC teams assemble all technical documents including manufacturing process descriptions, batch records, validation protocols/reports, stability data, and analytical methods documentation. These documents are internally reviewed for scientific and GMP compliance before sharing with Regulatory Affairs.
4. Submission Dossier Assembly: Regulatory Affairs consolidates CMC data into the dossier structure following established regulatory formats (e.g., CTD – Common Technical Document). Draft dossiers undergo cross-functional review including QA approval prior to submission.
5. In-Process Controls and Verification: Throughout dossier preparation, version controls and change tracking are maintained by document control teams. Periodic status meetings between CMC and Regulatory Affairs ensure transparency of progress and early identification of deficiencies.
6. Handling Regulatory Queries: Upon receipt of regulatory queries related to CMC data, Regulatory Affairs liaises with CMC teams for prompt investigation, data verification, and generation of response documents. All communications and justifications must be documented diligently.
7. Approvals and Finalization: Final dossier versions require approvals from department heads in Regulatory Affairs, CMC, and QA. Upon approval, documents are archived in controlled systems and submitted to the applicable regulatory authorities within specified timelines.
8. Record Keeping and Retention: All coordination-related records, emails, meeting minutes, correspondence, and submission records are retained as per organizational and regulatory requirements to support audit readiness and traceability.
9. Closure and Continuous Improvement: After dossier submission and final regulatory clearance, teams conduct a post-submission review to capture lessons learned. Identified gaps or improvement opportunities are incorporated in process updates or training initiatives.
Adherence to this procedural workflow ensures regulatory dossiers are accurate, comprehensive, and submitted timely, reducing risk of non-compliance and facilitating efficient product registration and lifecycle management.
Abbreviations
CMC: Chemistry, Manufacturing, and Controls
QA: Quality Assurance
GMP: Good Manufacturing Practice
CAPA: Corrective and Preventive Action
CTD: Common Technical Document
Documents
- Coordination Meeting Minutes Template (Annexure-1)
- Regulatory Submission Tracking Log (Annexure-2)
- Regulatory Query Response Form (Annexure-3)
References
– ICH Q10 Pharmaceutical Quality System Guideline
– ICH M4 Common Technical Document (CTD) Format
– FDA and EMA Regulatory Submission Guidelines
– Organization Quality Management System Policies
– GMP Guidelines and Documentation Standards
Version
1.0
Approval
| Prepared By | |
| Checked By | |
| Approved By |
Annexures
Annexure-1: Coordination Meeting Minutes Template
Purpose: To document discussions, action items, and decisions made during coordination meetings between CMC and Regulatory Affairs teams to ensure clarity and follow-up.
| Meeting Date | 10/04/2026 |
| Location | Conference Room A / Virtual |
| Attendees | CMC Lead, Regulatory Affairs Lead, QA Representative, Document Control |
| Facilitator | Regulatory Affairs Lead |
Agenda Items:
- Review of dossier preparation status
- Discussion on validation data completeness
- Submission timeline alignments
- Regulatory query handling plan
Meeting Notes/Decisions:
- All CMC reports to be finalized by 12/04/2026
- QA to perform compliance check before document handover
- Regulatory Affairs to update dossier template per latest guidelines
Action Items:
| Action | Responsible | Due Date |
|---|---|---|
| Finalize validation reports | CMC Team | 12/04/2026 |
| Perform QA document review | QA Team | 13/04/2026 |
| Update submission tracker | Document Control | 14/04/2026 |
Annexure-2: Regulatory Submission Tracking Log
Purpose: To maintain a centralized record of all regulatory submissions coordinated between CMC and Regulatory Affairs including submission dates, dossier versions, and regulatory authority details.
| Submission ID | Product Name | Dossier Version | Submission Date | Regulatory Authority | Status |
|---|---|---|---|---|---|
| SUB2026-001 | Product A | V3.2 | 15/04/2026 | FDA | Under Review |
| SUB2026-002 | Product B | V1.0 | 10/04/2026 | EMA | Accepted |
| SUB2026-003 | Product C | V2.1 | 12/04/2026 | PMDA | Request for Information |
Annexure-3: Regulatory Query Response Form
Purpose: To systematically document and address queries received from regulatory authorities relating to CMC information within submissions, ensuring timely and compliant responses.
| Query Reference No. | RQ-2026-045 |
| Received Date | 20/04/2026 |
| Product Name | Product A |
| Regulatory Authority | FDA |
| Query Description | Clarification requested: Manufacturing process validation batch sizes discrepancy explanation. |
| Investigation Conducted By | CMC Technical Team |
| Response Prepared By | Regulatory Affairs Team |
| Response Submission Date | 28/04/2026 |
| Response Summary | Validation batch sizes differ due to scale-up strategy; detailed justification and comparative data provided. |
| Status | Closed |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
| 13/04/2026 | 1.0 | Initial issue | New SOP creation |